New drug hope for rare inflammatory VEXAS syndrome
NCT ID NCT07098936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug momelotinib in 57 people with VEXAS syndrome, a rare inflammatory condition that may also involve a bone marrow disorder called MDS. Participants receive momelotinib daily, and doctors check if symptoms improve and if steroid doses can be lowered. The study first finds the safest dose, then measures how well the drug controls the disease over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
momelotinib
What this could lead to
If it works, this could offer a new treatment option to control VEXAS syndrome symptoms and reduce reliance on steroids.
What could go wrong
This is an early phase 2 trial with only 57 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELO DYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Lyon sud - Service d'Hématologie Clinique
RECRUITINGPierre-Bénite, 69495, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU Estaing - Service d'Hématologie Clinique
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU Nantes - Hôtel Dieu - Service d'Hématologie Clinique
NOT_YET_RECRUITINGNantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU d'Angers - Service des Maladies du sang
NOT_YET_RECRUITINGAngers, 49933, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Haut-Lévèque - Centre F. Magendie - Service des Maladies du sang
NOT_YET_RECRUITINGPessac, 33604, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Tours - Hôpital Bretonneau - Service de Médecine Interne
NOT_YET_RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Claude Huriez - Service de Médecine Interne
NOT_YET_RECRUITINGLille, 59037, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Pontchaillou Service d'hématologie clinique et service de médecine interne
NOT_YET_RECRUITINGRennes, 35033, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Saint Louis - Service hématologie séniors
NOT_YET_RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Saint-Antoine - Service de Médecine Interne
NOT_YET_RECRUITINGParis, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IUCT Oncopole Département d'hématologie / Unité de médecine interne
NOT_YET_RECRUITINGToulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact